JHS Svendgaard Laboratories has announced a board meeting to revise the utilization of Rs. 30 Cr from its preferential issue.

The funds will now focus on equipment acquisition (Rs. 6 Cr), strategic capital infusion in associates for expansion (Rs. 16.5 Cr), and general corporate purposes (Rs. 7.5 Cr). The timeline is extended to December 2026, shifting strategy from a new project in J&K to boosting manufacturing capacity and subsidiary growth.